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The effects of intracerebrally administered gamma-aminobutyric 
acid (GABA) and related compounds and the anticonvulsant activity of 
systemically and intracerebrally administered GABA were studied in mice. 
Systemic administration of GABA in doses of 1 g/kg or less did not in- 
duce neurotoxicity or exhibit anticonvulsant activity. Intracerebrally 
administered GABA, glycine, B-alanine and 5-amino-n-valeric acid 
elicited clonic movements followed by depression which increased in in­
tensity as the doses of the compounds were increased when loss of 
righting reflex was used as the criteria of depression. GABA and B- 
alanine were of equimolar potency and were more active than glycine and 
5-amino-n-valeric acid which were equipotent. Intracerebrally adminis­
tered 6-amino-n-caproic acid and 8-amino-n-caprylic acid induced clonus 
followed by tonic extensor seizures. The number of animals exhibiting 
tonic extensor seizures increased as the dose of the amino acids 
increased. 8-amino-n-caprylic acid was approximately ten times as 
potent as 6-amino-n-caproic acid on a molar basis. Clonus due to 
pentylenetetrazol (0.5% IV and 87.5 mg/kg SC) and convulsions due to 
minimal electroshock were prevented in low doses (20-60 ug/20 g) and 
potentiated in higher doses (80-160 ug/20 g) of intracerebrally 
administered GABA. Tonic extensor seizures and death induced by 
pentylenetetrazol (0.5% IV) were prevented by intracerebrally adminis-
tered GABA. Clonus and tonic extensor seizures induced by caffeine
potentiated by intracerebrally administered GABA. Strychnine (1.25 mg/ 
kg SC) convulsions or those induced by supramaximal electroshock were 
not altered by intracerebrally administered GABA.
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INTRODUCTION
Hawkins and Sarett (3*0 reported that orally administered gamma- 
aminobutyric acid (GABA) exhibits anticonvulsant activity against 
convulsions induced by methylethylglutarimide or pentylenetetrazol 
(ED50 200 mg/kg and kOO mg/kg) in mice. Florey and McLennan (28) re­
ported that the subcutaneous injection of purified brain extracts 
which may contain GABA as an active constituent (6, 7) proteoted mice 
against strychnine induced convulsions. A similar observation was made 
for GABA itself by McLennan (58). Conversely, other investigators 
could not demonstrate any anticonvulsant action for GABA (12, 88). 
Furthermore, the observations of Purpura et al. (69) and van Gelder 
and Elliott (9*0 that systemically administered GABA does not cross 
the blood brain barrier tend to preclude a significant anticonvulsant 
effect for the systemically administered compound. In view of ihe 
controversies in the literature concerning the anticonvulsant actions 
of systemically administered GABA, the following study was undertaken. 
The purpose of this study was threefold:
1) To investigate the anticonvulsant action of systemically admin­
istered GABA against convulsions produced by several procedures.
2) To study the anticonvulsant action of the compound when adminis­
tered intracerebrally;
3) To investigate the central nervous system actions of related com­
pounds and compare their activity with that of GABA.
REVIEW OF LITERATURE
It is not surprising that the pioneer observations of Ackerman 
(2) on the production of gamma-aminobutyric acid (GABA) from glutamic 
acid by the action of putrefying material and the failure to confirm 
this observation by Abderbalden et al. (l) two years later aroused no 
interest among scientists for some time since instances of this kind 
are not new and are not difficult to find in the scientific literature.
The demonstration of the presence and/or production of GABA in 
various bacteria (29» 97) led to its identification in a number of liv­
ing systems such as yeast extract (72), Bramby's seedling apples (4l), 
fresh beet roots (95) > potato tubers (87) and barley roots (8).
Roberts et al. (79) and Awapara et al. (4) simultaneously and independ­
ently observed that the brain tissue of various mammalian species con­
tained relatively large amounts of GABA in a predominantly free form. 
Udenfriend (93) positively identified the substance in brain by the use 
of isotope tracer techniques.
Relationship Between Factor I and GABA:
Florey (23, 2k) observed that certain extracts of mammalian cen­
tral nervous system exerted inhibitory and excitatory effects upon the 
discharge of the crayfish stretch receptor neuron. The portion of the 
extract responsible for the inhibitory action was designated as Factor
I and extracts containing it were called "Factor I extracts". The 
method utilizing the crayfish has been simplified and standardized and 
has been used for the assay of Factor I activity (19, 22). With the 
aid of this assay procedure, Bazemore et al. (6, 7) concentrated
3Factor I activity from a large quantity of beef brain. This material 
was crystallized and identified as GAM by infra red spectroscopy and 
paper chromatography. Estimates of the GABA content of the brain by 
Factor I assay agreed reasonably well with those obtained by the chemi­
cal methods. Synthetic GABA also showed the same activity as the 
isolated material using this assay procedure. It seems likely, there­
fore, that the GABA content of the brain could account for virtually 
all the Factor I activity. It is of interest to note that the physio­
logical properties of Factor I and GABA were studied independently be­
fore it was recognized that a relationship existed between Factor I and 
GABA.
Recently, McLennan (58) observed that GABA did not duplicate the 
actions of Factor I on the squid rectum and the monosynaptic reflex in 
the cat. McLennan (59) has also reported that GABA could not be detect­
ed chromatographically in a partially purified brain extract which 
showed a good deal of Factor I activity. McLennan, therefore, has 
suggested that such extracts contain at least one other active prin­
ciple which possesses those physiological actions not exhibited by GABA 
or a precursor of GABA which is active on the stretch receptor. Elliot 
and Jasper (21) have suggested that other inhibitory factors which are 
not detected by the use of crayfish stretch receptors may be present. 
Further, a number of substances and preparations from brain have been 
found to exert inhibitory actions.
The evidence in favor of the suggestion that the activity of 
Factor I is due to its GABA content is not conclusive, but is strong 
and therefore in what follows the two will be discussed together.
kDistribution of GAM and Factor I in Animal Tissues:
Tallan et al. (92) estimated the GABA content of various tissues 
in a cat and based on wet tissue weight, found 23.4 mg/lOO g in the 
brain and less than 1 mg/lOO g or ml in liver, pancreas, urinary 
bladder, kidneys, gastrocnemius muscle, urine, and plasma. Chromato­
grams of the saliva (6l) and gastric juice of normal fasting individ­
uals (30) always showed the presence of small amounts of GABA. GABA 
has also been demonstrated in the retina and choroid of the dog and ox, 
but not in the iris and ciliary body (50). Although GABA is not 
present in mammalian peripheral nerve (79) small amounts of GABA have 
been detected in the sciatic nerve of hens (65). Logothetis (55) de­
tected 0.4/ig/ml GABA in the cerebrospinal fluid of man and dog, and 
Knauff (49) showed the presence of GABA in the cerebrospinal fluid of 
normal human subjects and others suffering from various neurological 
and non-neurological diseases. However, van Gelder and Elliott (9*0 
could not detect Factor I activity in the cerebrospinal fluid drawn 
from human subjects suffering from a variety of conditions.
No Factor I activity has been detected in extracts of liver, 
spleen, cardiac muscle, mammalian sciatic nerve or sympathetic ganglia 
(27) although small amounts of Factor I activity have been found in 
peripheral nerves of crustaceans (24).
Factor I or GABA activity has been found in the central nervous 
system of many non-mammalian and mammalian species (24, 73) • Florey 
and Florey (26) demonstrated that the grey matter of extrapyramidal 
centers, superior cerebral peduncle, optic tract and crus cereberi of 
beef brain have pronounced Factor I activity.
5Though GABA has been found in unhydrolysed brain extracts (**-, 76, 
92), most of the Factor I activity in the brain is present in an 
•occult* condition from which it can be readily released by heat, by 
suspension of the tissue in hypotonic medium, or by treatment with mild 
acid or alkali (19)* It has been suggested (2l) that GABA in the brain 
occurs in three formss a minimal amount present in cell-free media, a 
portion which is readily released on homogenization and a larger amount 
which is strongly occluded.
Formation and Breakdown of GABA?
Most strains of E. coli, Proteus vulgaris, B. subtlis and B-mesen- 
teroides and some strains of Clostridia produce 1-glutamic acid decarb­
oxylase which requires pyridoxal phosphate as a coenzyme (29). Schales 
et al. (82) have also demonstrated the presence of this pyridoxal 
phosphate-dependant enzyme in plants.
Roberts et al. (79) and Awapara et al. (^f) in their experiments on 
the isolation of GABA from the mammalian brain tissue suggested the 
presence of a new type of enzyme capable of decarboxylating 1-glutamic 
acid. However, the actual demonstration of such an enzyme system did 
not come until somewhat later (77» 78, 9^ ). The enzyme was found to be 
dependent upon pyridoxal phosphate as a co-enzyme, was inhibited by 
semi car bazide and hydroxylamine, had an optimum pH of 6.^ 6.5 and was 
specific for 1-glutamic acid. Though an equilibrium constant for 1- 
glutamic decarboxylase has been demonstrated (70 at 25-27° C) by 
Koppelman et al. (5l)> earlier work suggests that the reaction goes 
virtually to completion. An extremely rapid production of GABA from 
1-glutamic acid has been demonstrated by a radioisotope tracer
6technique (81). A wide species variation in the 1-glutamic decarboxy­
lase activity and also variation in different areas of the brain has 
been demonstrated (56). In general, the 1-glutamic decarboxylase 
activity was greater in the granular layer than in the molecular layer 
of the brain and the activity in the grey matter was much higher than 
that in the white matter. This confirms the earlier observations of 
Roberts et al. (80) that 1-glutamic acid decarboxylase is present chief­
ly in the grey matter of the central nervous system. Roberts et al.
(80) presented evidence which suggested that glutamic decarboxylase 
activity increased in the embryo as maturation progressed. Other tis­
sues do not show as much enzyme activity as the brain.
A system transaminating GABA and alpha-ketoglutaric acid to yield 
glutamic acid and succinic semialdehyde has been demonstrated in rat, 
rabbit and calf brain homogenates and to a lesser extent in rat liver 
"particles’.' No enzyme for catalyzing this reaction could be demonstrat­
ed in rat kidney "particles" This GABA-alpha-ketoglutarate transamina­
tion reaction is reversible and, in the brain, the entire enzymatic 
activity is found in the insoluble"particles"(lO). In a similar system 
brain and liver residues and acetone powders of mouse brain, both GABA 
and B-alanine have been shown to transaminate with alpha-ketoglutarate 
(75)• The transaminase, like the decarboxylase, is dependent upon 
pyridoxal phosphate as a coenzyme. However, the apoenzyme of 1- 
glutamic acid decarboxylase seems to have a lower affinity for the co­
enzyme than that of GABA transaminase (cited from Roberts, et al. 81).
Baxter and Roberts (5) reported that grey matter of beef brain is 
a far richer source of GABA transaminase than white matter. The pH 
optimum of the enzyme is 8.2 and substrate specificity has been shown.
7Alpha-ketoglutarate seems to be the only effective amino group acceptor 
but specificity with regard to amino group donor is less clear since 
several omega-amino acids other than GABA transaminate with alpha-keto- 
glutarate. A free sulphydryl(-SH) group may be necessary for the 
functioning of the enzyme since it is inhibited by iodoacetamide, p- 
chloromercuribenzoate and N- ethy1-maleimide. Alpha-ketoglutarate and 
pyridoxal phosphate protect the enzyme from heat inactivation.
Albers and Salvador (3) have demonstrated in the brain a soluble 
DPN dependent dehydrogenase which catalyses the oxidation of succinic 
semialdehyde. A similar enzyme, more active with TEW than with DPN, has 
been obtained from a strain of Pseudomonas (83). It has, therefore, 
been suggested (73, 81) that in the brain a shunt operates around the 
alpha-ketoglutarate oxidase system of the tricarboxylic acid cycle. In 
this shunt alpha-ketogluaric acid could be withdrawn through the forma­
tion of glutamic acid by transamination with GABA and the carbon chain 
of GABA could enter the cycle at the succinate level. Pisano et al.
(64) have demonstrated that enzymes in the kidney and liver catalyse 
the transamidination between GABA and arginine to yield gamma-guanidino- 
butyric acid which has been isolated from brain and kidney (42). Rabbit 
brain,,particles"have been shown (84) to convert GABA to gamma- amino- B- 
hydroxy butyric acid in a reaction for which ATP, FAD were absolute 
requirements and Mg ions accelerated the reaction, while methylene 
blue and nitrophenol inhibited the reaction.
Possible Role of GABA as an Inhibitory Transmitter Substance in the 
Brain:
When substances are identified in the central nervous system, it
8is natural to inquire into their function and thus they may become 
candidates for various roles, including that of potential neurohumoral 
transmitters. This is now the case with GABA which has been suggested 
as a possible inhibitory transmitter in the central nervous system.
The evidence for the chemical transmission at the neuromuscular junc­
tion is based upon the fulfillment of the following criteria (63)* The 
presynaptic neuron should l) synthesize the transmitter and release 
it in a pharmacologically identifiable form. 2) The action of the 
transmitter on the postsynaptic cell should reproduce the specific 
events of normal transmission, and should be antagonized by competitive 
blocking agents. 3) There should exist an enzyme capable of destroying 
the transmitter. With regard to the possible role of GABA as an inhi­
bitory transmitter, the available literature will be evaluated in the 
light of these criteria.
The evidence that GABA is synthesized in the presynaptic neuron in 
the central nervous system is indirect, but is suggested by the follow­
ing observations: l) differential localization of Factor I in the 
central nervous system (2*1-, 26), 2) concomitant occurrence of 1- 
glutamic acid decarboxylase with GABA in large amounts in the grey 
matter of the brain (80), 3) the embryological appearance of 1-glu­
tamic acid-decarboxylase and GABA with maturation of the brain (80),
4) the inability of GABA to cross the blood barrier (69, 9*0 •
Although it could be assumed that GABA is released by the pre­
synaptic neuron, Hayashi and Nagai (36) and Hayashi (35) believe "that 
gamma-amino-B-hydroxy-butyric acid is more important as an inhibitory 
transmitter. Lissak and Endroczi (5*0 have presented evidence for the 
existence of an inhibitory factor in the brain which seems to differ
9somewhat from Factor If while Purpura et al* (68) have suggested that a 
number of vitamins and amino acids may be of physiological and patho­
logical significance as agents affecting the central synapse* Further­
more, the experimental proof for the release of GABA by neurons in 
amounts adequate to block transmission of impulses in the central 
nervous system is not yet available#
Florey (25) has shown that GABA mimics the stimulation of the 
inhibitory cardiac fibers in the lobster heart as well as in crayfish 
stretch receptor# The effects of GABA on certain membrane phenomena 
are similar to those of the naturally occurring inhibitory transmitter 
(52). Purpura et al. (66) have demonstrated that the local application 
of GABA to the surface of the cortex inhibited the excitatory synapses 
rapidly and reversibly. In a more extensive report, Iwama and Jasper 
(^ 3) have confirmed these findings# Purpura et al# (67) investigated 
a number of omega-amino acids applied topically to the surface of the 
cortex and presented evidence for the presence of inhibitory synapses 
in the superficial layers of the cortex# While comparing GABA with 
acetylcholine as a transmitter substance in the central nervous system, 
Killam (46) has suggested that GABA might be elaborated by inhibitory 
brain cells.
Semicarbazides and related compounds have a convulsive action (45, 
47) and these convulsions develop only after a latent period of one 
hour. They are associated with a reduction of GABA content of brain, 
probably due to inhibition of the pyridoxine-dependant enzyme 1-glutamic 
decarboxylase and this decrease of intrinsic GABA level is also asso­
ciated with an increase in the size of the surface negative potential 
(48). The effect of semicarbazide was reversed by the administration
10
of vitamin Bg intravenously. Das Gupta et al. (17) were able to an­
tagonize electrically induced seizures in the hippocampus and on the 
cortex by the topical application of GABA and to increase seizures by 
blockade of GABA synthesis. Thus, alterations of cortical responses 
were produced by the manipulation of exogenous and endogenous brain 
levels of GABA. It is apparent, therefore, that the postulated ability 
of GABA to reproduce the specific events of normal transmission, is 
based on deductions derived from 'in vitro1 experiments or from results 
obtained following the local application of GABA to the cerebral 
cortical surfaces.
As yet no competitive blocking agents for GABA are known. GABA 
transaminase can inactivate GABA (10, 75) but the enzyme is less speci­
fic in this regard (5), and it remains an open question as to whether 
this reaction occurs in the inactivation of GABA in the intact cell. 
Furthermore, no drug is known that can selectively inhibit the trans­
aminase, but if such a drug is discovered, intrinsic levels of GABA 
could be increased in the brain and more critical information about the 
role of GABA in the brain could be derived.
The most decisive evidence for chemical transmission such as the 
collection and identification of the transmitter after stimulating the 
presynaptic neuron and the demonstration that the transmitter applied 
artificially can reproduce the characteristic post-synaptic events, has 
not yet been obtained for any specific central synapse.
Peripheral Actions:
Takahashi et al. (90) reported that intravenous injections of GABA 
into anesthetized rabbits caused a transient reduction in blood pressure,
11
bradycardia and stimulation of respiration. Similarly, a depression 
of blood pressure was previously reported for Factor I by Florey and 
McLennan, (27). In a subsequent study, Takahashi et al. (9l) postu­
lated depressor points in the medulla as the site of depressor action 
of GABA. Stanton and Woodhouse (86) observed respiratory stimulation, 
pressor followed by depressor responses and bradycardia with doses of
0.02-0.32 jamole/kg of GABA. On the basis of their data they suggest 
carotid sinus and aortic chemoreceptor stimulation as the mechanism of 
action of pressor and respiratory responses and peripheral ganglionic 
blockade as the mechanism for the depressor response. Elliott and 
Hobbiger (20) have reported considerable species variability, such as 
a fall in blood pressure with transitory bradycardia, respiratory de­
pression preceded by a single gasp in dogs, hypotension only in rabbits, 
no effects in unanesthetized rats with midbrain sections, but a transi­
tory rise in a similarly prepared monkey, and transitory gasping, 
various paresthesias and transitory bradycardia and hypotension with 
low doses in man.
Florey (24) observed that Factor I antagonized the action of acetyl 
choline on the guinea pig ileum and Hobbiger (38, 39) confirmed this 
for GABA and also demonstrated antagonistic effects to submaximal doses 
of nicotine, histamine and 5-hydroxytryptamine on the same organ.
Species differences between guinea pig, rat and rabbit were found. GABA 
alone produced stimulation and/or relaxation, the stimulating effects 
being abolished by atropine.
Although effects of GABA on peripheral ganglionic transmission have 
not been studied thoroughly, Florey and McLennan (27) found that puri­
fied brain extracts blocked synaptic transmission in the inferior
12
mesenteric and stellate ganglia of the cat. However, excitatory 
effects were observed on the hypoglossal nucleus of the same animal.
It is unlikely that GABA (52) or Factor I (27) have effects on 
nerve conduction or neuromuscular transmission.
Other Active Substances Related to Factor I and GABA:
Bazemore et al. (7) investigated a large number of amino acids 
utilizing the crayfish stretch receptor preparation and observed in­
hibitory activity, like that of GABA, with: l) DL, gamma-amino-B- 
hydroxy-butyric acid which was about one-half as active as GABA. 2) 
B-alanine and 5-amino-n-valeric acid which were ^ 20^ as active as GABA.
3) Alpha-gamma-diamino butyric acid which was V60^ as active. Gamma- 
guanidino butyric, which has been isolated from brains of dogs, cattle, 
and humans (42) also has some activity on the crayfish stretch recep­
tor (52). Hayashi and Nagai (36), Hayashi and Shuhara (37) and Hayashi 
(35) have found that convulsions induced in dogs by electrical stimula­
tion of the motor areas of the cortex or by cortical topical applica­
tion or by intracarotid or intraventricular injection of metrazol or 
glutamate could be inhibited by intracarotid or intraventricular injec­
tions of a number of omega-amino-acids. GABA and higher omega-amino- 
acids were usually inhibitory but sometimes showed excitatory activity. 
The inhibitory activity of L, gamma-amino-B-Hydroxybutryic acid was 
approximately ten times that of GABA. Hayashi (35) believes that 1- 
gamma-amino-B-hydroxybutyric acid can be derived from GABA, and is more 
significant as an inhibitory substance.
On the basis of evidence presented by Lissak and Endroczi (54) it 
would seem that extracts of neural tissue contain at least one other
13
principle which would distinguish it from Factor I.
Hosein (40) has isolated gamma-butyrobetaine from brains removed 
from rats and cats suffering convulsions induced by a variety of con- 
vulsant drugs. Intracerebral injection of small amounts of this sub­
stance produced violent and fatal convulsions in unanesthetized animals. 
Gramma-amino-butyryl choline has been isolated chromotographically from 
dog brain by Kuriaki et al. (53) who observed that this substance exerts 
a variety of peculiar effects like muscarine* nicotine, atropine and 
antihistamines, and therefore suggest that it might be an inhibitory 
neurotransmitter.
MATERIALS M B  METHODS
Fifteen hundred adult male albino mice (Webster Strain, National 
Laboratory Animal Company) varying in weight from 20-25 g were used in 
this investigation. The animals were maintained on Purina Laboratory 
Chow and were allowed free access to food and water at all times. The 
following compounds were tested: glycine, B-alanine, GABA, 5~amino"n_ 
valeric acid, 6-amino-n-caproic acid and 8-amino-n-caprylic acid. Each 
of the compounds was administered either systemically or intracerebral- 
ly. In the case of systemic administrations, the agents were dissolved 
in normal saline and were administered in the appropriate doses either 
intravenously into the lateral tail vein, subcutaneously or orally by 
means of intubation. The injection volume used with these systemic
routes never exceeded 0.38 ml.
The procedure used for the intracerebral injections was essentially 
that described by Haley and McCormick (33). The test agents were dis­
solved in Locke-Ringer's solution containing sodium bicarbonate. The 
injection volume for each dose of each drug was 0.01 ml. Control animals 
received 0.01 ml of Locke-Ringer's solution. The pH of the resultant 
solutions of amino acids varied from 7,0-7A, With taurine, which was 
quite acid, it was necessary to add more sodium bicarbonate to obtain 
a pH 7.0. Control mice which were to be compared with animals receiv­
ing taurine received Locke-Ringer’s solution containing the additional 
quantity of sodium bicarbonate which had been needed to neutralize the
taurine solution.
The following anticonvulsant tests were employed throughout the
investigation:
15
1. Subcutaneous pentylenetetrazol test, (l3)» I*1 this pro­
cedure mice were administered 87.5 mg/kg pentylenetetrazol subcutan- 
eously and were observed for the appearance of clonic movements of the 
head and face lasting for at least 7 seconds. Animals not exhibiting 
clonus were considered protected.
2. Subcutaneous strychnine test. In this procedure each animal 
received 1.25 mg/kg strychnine nitrate subcutaneously. Abolition of 
the tonic extensor phase of the convulsion was considered as protection.
3. Timed intravenous infusions of pentylenetetrazol 0.% strych­
nine nitrate 0.01$, ammonium acetate jfo and caffeine Vfo (62, l^ f).
The amount of the intravenously administered convulsant required 
to produce first signs of tonic extension of the hind limbs and respira­
tory arrest was noted. In the case of pentylenetetrazol and caffeine 
infusions, the amount required to produce first signs of clonic seiz­
ures was also recorded. In all cases the convulsant was infused at the 
rate of 0.05 ml/lO seconds. The total injection volume never exceeded 
1.0 ml per mouse; the animal was considered to be protected from the 
extensor component of the seizure when tonic extension of the hind limbs 
did not occur after 1.0 ml of the convulsant had been delivered.
Minimal electroshock seizure threshold test (MET) as describ­
ed by Swinyard et al. (89).
5. Supramaximal electroshock seizure pattern test (MLS) as des­
cribed by Swinyard et al. (89).
The amino acids used in this investigation were obtained from Cal­
ifornia Foundation for Biochemical Research.
The statistical connotation and procedures used to evaluate the 
data obtained in this study are those outlined by Bliss (ll) and
16
Snedecor (85).
.
.rl ««’#!«• i-
RESULTS
Svstemically Administered GABA
Tables I and II summarize the results obtained with various con­
vulsant test procedures following the systemic administration of GABA. 
The first convulsant test employed was the timed intravenous infusion 
test of Orloff et al. (62) in which pentylenetetrazol (0.5$) was the 
convulsant agent studied. As can be seen in Tables I and II, no sig­
nificant protection against pentylenetetrazol-induced clonus or tonic 
extensor convulsions and death was observed regardless of the dose of 
GABA administered or the time interval between the administration of 
GABA and the start of the intravenous infusion of pentylenetetrazol.
In another experiment, GABA was administered in a dose of 400 mg/kg 
(orally) and studied after two hours for anticonvulsant activity against 
the clonus induced by pentylenetetrazol (100 mg/kg SC). Again no pro­
tection was observed utilizing this convulsant test at two hours follow­
ing the oral administration of the GABA dose. As can be seen in Table
I and II, 1 g/kg doses of GABA administered either subcutaneously or 
intravenously induced no significant protection against strychnine ni­
trate (SC), ammonium acetate (IV infusion), caffeine (IV infusion), 
minimal electroshock or supramaximal electroshock. Although 20fo pro­
tection was observed when strychnine (SC) was administered immediately 
after the 1 g/kg (IV) dose of GABA, this degree of protection was not 
considered of significance since the dose of GABA employed was very 
large and since no protection had been observed previously when GABA 
400 mg/kg (SC) had been studied at various time intervals for its anti­
convulsant activity against strychnine nitrate given by the timed 
intravenous infusion technique. The validity of several of the con-
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vulsant tests utilized was assessed by the use of reference anticonvul­
sants. The results of these tests are summarized in Table III. It 
should be noted that the results compare favorably with those obtained 
by other investigators and therefore the anticonvulsant testing proce-- 
dures were considered to be valid.
GABA administered by the oral, subcutaneous or intravenous route 
(in doses of 1 g/kg or less) did not induce discernible evidence of 
neurotoxicity when the critera for this response as outlined by Swin­
yard et al. (89) were utilized. Systemic GABA in doses of 1 g/kg or 
less did not prolong the latency period required for the onset of con­
vulsive patterns elicited by strychnine nitrate (SC), pentylenetetrazol 
(SC), minimal electroshock or supramaximal electroshock.
Effects of Intracerebral Administration of GABA and Some Related Amino 
Acids
In contrast to the results obtained following the systemic admin­
istration of GABA, injection of GABA intracerebrally induced reproduc­
ible and significant evidence of neurotoxicity. Doses of GABA from 10- 
160 ps/20 g body weight administered intracerebrally induced a biphasic
response pattern. Within 6 to k2 seconds following the administration
i
of GABA intracerebrally, the animal showed distinct clonic-type move­
ments such as facial and front leg clonus. At this time the animal was 
hyperexcitable to touch and external stimuli. The intensity of excite­
ment did not seem to increase as the dose of the compound was increased. 
The duration of this initial clonus varied widely from 12 seconds to 
2.5 minutes and was not regularly influenced by the size of the dose of 
GABA administered. The period of hyperexcitability was then followed
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by depression, the intensity of depression varying with the dose of 
GABA employed. In lower doses (10-60 pg/20 g) the animals were simply 
depressed as exemplified by their inability to walk the rim of a cage, 
loss of exploratory activity, drowziness and slowing of respiratory 
rate. However, as the dose was increased, loss of righting reflex 
occurred in certain animals; the number of animals showing loss of 
righting reflex increasing as the dose of the amino acid administered 
was increased. Apnea was observed in many mice at doses of from 80—
160 fig/20 g and in some of these animals death resulted from respira­
tory arrest. However, there did not seem to be a regular relationship 
between the dose of GABA causing loss of righting reflex and that caus­
ing death, and the major portion of the animals exhibiting loss of 
righting reflex recovered within 2.8-8.3 minutes following GABA admin­
istration. A number of the animals exhibited hyperexcitability and 
mild front limb and facial clonus following the depression phase. In 
some cases, the same volume of Locke-Ringer1s solution, injected intra­
cerebrally in controls, elicited a 1-5 second period of stunning, but 
only a small number of animals showed signs of neurotoxicity and damage
following this stunning period.
Similar responses were observed following the intracerebral admin­
istration of glycine, B-alanine and 5-amin0-n_va.1 eri c acid. However, 
it seemed that the initial clonic phase was greatest in intensity with
5-amino-n-valeric acid and least with glycine. Taurine induced loss of 
righting reflex and death in some animals in doses of 320-640 yxg/20 g. 
However, no constant dose-effect relationship could be demonstrated at 
these doses. Dose-effect relationships were obtained from data obtain­
ed on the loss of righting reflex induced by the other compounds. A
2k
summary of these experiments with appropriate statistical analyses is
presented in Part A of Table IV. It should be noted ihat the dose
2response curves for all the compounds are linear as shown by X^ values 
for each curve. Table V (Part A) summarizes the comparison of "the mo­
lar potency of each compound as compared to GABA (1.00). It should be
noted from X 2 in -this table that the curve for GABA was parallel in P
each case with the curve for the compound with which it was being com­
pared. Examination of the 95/'° confidence intervals for ED^q's derived 
for each of the compounds revealed that GABA and B-alanine were essen­
tially of the same potency in eliciting the loss of righting reflex. 
Glycine and 5-amino-n-valeric acid were essentially equipotent but less 
active than GABA and B-alanine.
Omega-amino acids of chain lengths greater than five carbons pro­
duced no depressant effects} only excitatory effects were seen. Intra- 
cerebral administration of 6-amino-n—caproic acid and 8-amino—n-capry- 
lic acid elicited primary facial and forelimb clonus which was followed 
in certain animals by tonic extensor convulsions. The number of animals 
exhibiting the tonic extensor effect increased as the dose of the par­
ticular compound increased. Table IV (Part B) summarizes the data ob­
tained with these excitatory amino acids. It should again be noted that 
a linear relationship between dose and effect occurred as indicated by 
the XL2 values listed in the Table. Table V (Part B) contains the po­
tency comparison between 6—amino—n—caproic and 8—amino—n—caprylic acid.
2g^n-in these curves were found to be parallel as shown by the X^ value.
6-amino-n-caproic acid was found to be 0.106 times as potent as the 
8-amino compound in eliciting tonic extensor convulsions.
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Effect of Intracerebrally Administered GABA Upon Convulsive Seizures
Unless otherwise stated, the convulsive test procedures to be dis­
cussed were employed within 1 minute following the intracerebral admin­
istration of GABA.
Pig. 1 summarizes the effects of various doses of intracerebrally 
administered GABA upon clonic convulsive activity induced by pentylene­
tetrazol (87.5 mg/kg SC), pentylenetetrazol (IV infusion 0.5$) and 
minimal electroshock seizure threshold test. A biphasic response was 
observed as the dose of GABA was increased. Protection against clonus 
induced by pentylenetetrazol (IV) was observed in doses of 40, 60, 80 
Mg/20 g GABA. This protection was statistically significant (PC0.05) 
from the Locke-Ringer1s controls when 80 Mg/20 g GABA had been admin­
istered. A similar trend was observed with pentylenetetrazol (SC) and 
minimal electroshock when doses of GABA of 60 and 80 Mg/20 g and 10, 20, 
40 and 80 )ig/2Q g respectively were administered. When doses of GABA 
greater than 80 jug/20 g were administered, the clonic convulsant 
activity of pentylenetetrazol increased and when 160 jig/20 g of GABA 
was administered, less pentylenetetrazol was required to induce clonus 
than had been previously required for the Locke-Ringer controls (P<0.05). 
The number of animals showing clonus with pentylenetetrazol (SC) was 
greater following GABA (160 Mg/20 g) than following the injection of 
Locke-Ringer's solution. Similarly, less protection against minimal 
electroshock was observed following 120 yxg/20 g GABA than following 
20, 40, and 80 jag/20 g.
The effects of intracerebrally administered Locke-Ringer1s solution 
and GABA upon tonic extensor convulsions and/or death induced by penty­
lenetetrazol (IV infusion, 0.5$) and strychnine nitrate (1.25 mg/kg, SC
28
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Figure I.
Effects of intracerebrally administered GABA upon clonic convulsions 
due to pentylenetetrazol (87*5 mg/kg SC and 0.5i° IV) and minimal 
electroshock.
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and. IV infusion 0.01$) are summarized, in Fig. II. GABA (20-160 p.g/
20 g), administered intracerebrally, did not protect the animals against 
tonic extensor convulsions induced by strychnine nitrate (SG or IV in­
fusion). However, in doses of 120 and 160 jog/20 g, GABA protected 
against tonic extensor convulsions and death induced by the intravenous 
infusion of pentylenetetrazol. It should also be noted that as the dose 
of GABA was increased many of the mice receiving the intravenous infu­
sion of pentylenetetrazol died without exhibiting tonic extension of 
the hind limbs. GABA, administered in doses of 20, kO and 80 jig/20 g 
did not protect against tonic extensor convulsions induced by supra­
maximal electroshock (50 mA, 0.2 sec. duration). The latency period 
required for the onset of tonic extensor convulsions induced by strych­
nine nitrate (SC) or supramaximal electroshock, was not altered by GABA 
regardless of the dose administered.
Caffeine and ammonium acetate were also utilized as convulsants 
in this investigation. The influence of intracerebrally administered 
GABA upon the convulsant activity of these agents was investigated and 
the results of these studies are summarized in Pig. III. The clonic 
convulsive and tonic extensor convulsive activity, induced by the intra­
venous infusion of caffeine 1°/ot was increased by the prior administration 
of GABA (5-80^/20 g). A statistically significant ( P C0 .0 5) reduc­
tion in the amount of caffeine required to induce clonus was observed 
following GABA (20, kO and 80 jag/20 g). Less caffeine was required to 
induce tonic extensor convulsions following 10, 20, 40 and 80 jug/20 g 
of GABA than was required to induce tonic extensor convulsions in the 
controls receiving Locke-Ringer’s solution only (P^O.05). In the 
case of ammonium acetate, significantly less convulsant (P<0.0 5)  was
v t • oir-' . .4 iz rL ' £ « ‘xs>frainitCu- i o  a ; t e s Y iS
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Effects of intracerebrally administered GABA upon tonic extensor 
seizures due to strychnine nitrate (1.25 mg/kg SC and 0.01$ IV) and 
pentylenetetrazol (0.5$ IV).
Figure II.
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Figure III.
Effects of intracerebrally administered GABA upon clonic convulsions 
due to caffeine (l#  IV) and tonic extensor seizures due to caffeine 
(lio IV) and ammonium acetate (5$ IV).
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required to induce tonic extensor convulsions in the animals receiv­
ing GABA 40, 80 and 100 jug/20 g than was required for those receiving 
Locke-Ringer's solution only (P<C0.05).
The duration of action of intracerebrally administered GABA was 
assessed in other studies by the use of pentylenetetrazol (IV infusion,
0.5$) and ammonium acetate (IV infusion, % )  following GABA (80 jug/20 
g)• In the case of pentylenetetrazol, protection was observed with 
GABA for 1-5 minutes following the injection} while with ammonium 
acetate, potentiation of convulsant activity was observed for 1-2 min­
utes following the administration of the amino acid.
DISCUSSION
The results obtained in the present investigation do not support 
the claims of certain investigators that systemically administered GABA 
will protect against certain convulsive seizures induced in mice by 
chemical means. Hawkins and Sarett (3^) reported that orally admin­
istered GABA afforded protection against convulsive seizures induced in 
mice by subcutaneously administered pentylenetetrazol or methylethyl- 
glutarimide. However, in the present study, it was not possible to 
demonstrate a protective action for orally administered GABA (400 mg/ 
kg) against pentylenetetrazol (100 mg/kg SC). This ^00 mg/kg dose of 
GABA is the protective dose 50 reported by Hawkins and Sarett (3^)» 
for orally administered GABA tested against pentylenetetrazol (100 
mg/kg SC). Other experiments summarized in Table I of the present 
study do not support the suggestion that systemic GABA possesses anti­
convulsant activity against pentylenetetrazol induced convulsions.
GABA, administered in doses of 1 g/kg (SC) did not afford protection 
against the clonic or tonic extensor seizures induced by the timed 
intravenous infusion of pentylenetetrazol (0.5$).
McLennan (58) reported that subcutaneously administered GABA 
(100 mg/kg) afforded protection against tonic extensor convulsions in­
duced in mice by strychnine (1.5 mg/kg I.P.). Elliott and Hobbiger 
(20) reported that GABA (SC) elicited a slight but variable protec­
tion against strychnine induced convulsion in mice. However, the de­
gree of protection observed was not statistically significant. Con­
versely, Brockman and Burson (12) could not demonstrate protection in 
mice when GABA (10-20 mg/total dose) was administered intraperitoneally
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and was followed five minutes later by strychnine kO jag (total dose IP). 
The results obtained in the present investigation did not indicate that 
systemically administered GABA protects against strychnine nitrate in­
duced convulsions. In one series of anticonvulsant tests, GABA (l gm/ 
kg IV) seemed to afford some protection against strychnine nitrate in­
duced convulsions, but this protection can hardly be considered of sig­
nificance since the dose of GABA was very large and the amount of pro­
tection observed was small (20^6). Furthermore, GABA (400 mg/kg SC) 
did not protect against tonic extensor seizures induced by the timed 
intravenous infusion of strychnine nitrate (0.01$) regardless of the 
time elapsing between GABA administration and the start of the strych­
nine infusion.
GABA, when injected systemically, did not alter the convulsant 
pattern elicited by other convulsant procedures such as minimal electro­
shock, supramaximal electroshock, caffeine infusion or ammonium acetate 
infusion. Furthermore, the latency period required for the onset of 
convulsions induced by pentylenetetrazol (SC), strychnine nitrate (SC), 
minimn.l electroshock or supramaximal electroshock was not altered by 
the prior systemic administration of GABA.
Systemically administered GABA not only lacks anticonvulsant 
activity, but it also lacks significant neurotoxicity when administered 
intravenously in doses of 1 g/kg. This lack of central nervous system 
activity could be explained in at least three ways: l) The compound 
does not readily cross the blood brain barrier; 2) The compound is 
rapidly destroyed in the peripheral tissues and adequate concentrations 
do not reach the brain; 5) The compound does not possess significant 
central nervous system activity which can be demonstrated by whole
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animal behavioral studies. The last possibility seems unlikely in view 
of the results obtained following the intracerebral administration of 
the compound in this study. In regard to the other two possibilities, 
some support exists for the first. Purpura et al. (69) reported that 
destruction of portions of the blood-brain barrier in cats significantly 
increased the neurophysiological activity of systemically administered 
GABA. Marrazzi et al. (57) observed that GABA abolished transcallosal 
conduction when the compound was given into the carotid circulation, 
but not when it was administered by the intravenous route. This obser­
vation can be interpreted as indicating that adequate concentrations 
of the compound do not reach the blood brain barrier following intra­
venous administration. Whether this is simply due to excessive dilu­
tion of the compound in the vascular system, or whether the compound is 
also rapidly destroyed peripherally by its passage through the liver 
circulation has not been determined. Experiments elucidating the rate 
of peripheral destruction of GABA would therefore seem in order.
One study indicates that rapid peripheral destruction of GABA may 
not be a significant factor in explaining the lack of central activity 
of GABA following the systemic administration of the compound, van 
Gelder and Elliott (9U) observed that Factor I activity, as determined 
by means of crayfish stretch receptor assay, increased significantly 
in various organs following the intraperitoneal injection of GABA. How­
ever, no increase of Factor I activity in the brain was observed. The 
Factor I activity of liver remained elevated for as long as 80 minutes 
following the GABA injection.
The effects of intracerebral administration of compounds to un­
anesthetized mice were first reported by Haley and McCormick (33)•
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Before a study of GABA and related amino acids was undertaken, a cer-
/
tain number of mice were administered acetylcholine and epinephrine in­
tracerebrally and responses reported by Haley and McCormick *33) were 
qualitatively reproduced. In the present study a quantitation of effects 
produced by the intracerebral administration of drugs in mice has been 
attempted. It was also observed in preliminary experiments that the 
intracerebral injection of Locke-Ringer’s solution produced less initial 
"stunning" effect than the injection of a similar volume of normal 
saline. Therefore, all the compounds tested in the present study were 
dissolved in Locke-Ringer's solution and this solution was used to ob­
tain controls for each procedure.
According to the original authors of the technique for intracere­
bral injection into mice, the site of injection and the length and gauge 
of the needle employed are critical factors. Hence, if the injection 
is performed too far rostrally, penetration into the ventricles will not 
be accomplished. Long needles tend to increase movements during the in­
jection, thus resulting in excessive brain damage. These variables were, 
therefore, rigidly controlled in the present study. In addition, the 
fluid volume and the pH of the solutions injected were kept constant. 
When all these factors were considered and kept constant, less than 5i° 
of the injected mice showed neurological symptoms which persisted for 
longer than 5 seoonds following the injection of Locke-Singer1s solu­
tion. It was felt, therefore, that although the intracerebral injec­
tion technique is rather crude and one cannot be certain about the exact 
site of injection, the method has merit inasmuch as a large number of 
unanesthetized animals can be studied, and as indicated in the results 
of this study, the effects elicited by certain active compounds
can be quantitated and dose-response relationship can be obtained.
As indicated in the results, the intracerebral administration of 
GABA to mice resulted in a biphasic response. The animal first exhibit­
ed clonic movements, which were then followed by depression. In addi­
tion, low doses of GABA protected against clonus induced by pentylene­
tetrazol and minimal electroshock. However, larger doses of ftABA tended 
to increase the incidence of experimentally induced clonus. It would 
seem, therefore, that GABA is not an anticonvulsant or depressant of 
the classical type (i.e., barbiturates). It is interesting to note that 
Hayashi (35) reported that GABA induced both excitatory and inhibitory 
effects when applied to the cortex of anesthetized dogs. He has postu­
lated that GABA is a precursor of two compounds in the central nervous 
system, a methylated derivative which is excitatory and gamma-amino-B- 
hydroxybutyric acid which is inhibitory only. It is rather difficult 
to explain the results of this study in the light of Hayashi's postu­
late. However, if the formation of the methylated derivative preceded 
the formation of the oxy derivative, one would expect to see a primary 
stimulation. This stimulation might then be followed by depression 
provided that the threshold for the hydroxy compound is lower and the 
equilibrium is in favor of the formation of this compound, in explana­
tion for why higher doses of GABA potentiate pentylenetetrazol and 
minimal electroshock induced clonus is not apparent, however, on the 
basis of this excitatory and inhibitory compound theory.
Chen et al. (13) suggested that compounds which antagonize the 
clonic seizures induced by pentylenetetrazol (SC or IV) or by a current 
of low intensity do so by the same neurophysiological mechanism. In 
the present study, GABA (intracerebrally) yielded qualitatively similar
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results when studied against the clonus induced by pentylenetetrazol 
(SC or IY infusion) or minimal electroshock. This essentially supports 
Chen's hypothesis. However, Chen and Bohner (15) and Goodman et al.
(3l) have also suggested that the tonic extensor convulsions induced 
by supramaximal electroshock and pentylenetetrazol (IV) occur by similar 
mechanisms. In the present study, intracerebrally administered G A M  
protected against the tonic extensor convulsions and death induced by 
pentylenetetrazol (IV infusion), but did not alter the tonic extensor 
seizure pattern elicited by supramaximal electroshock. These results 
suggest a different mechanism of action for the induction of tonic ex­
tensor seizures by the two procedures and therefore are not in agree­
ment with the nypothesis that the tonic extensor seizures are induced 
by a similar neurophysiological mechanism.
It would be of interest to speculate concerning the mechanism of 
action of the omega amino acids in terms of the classical pharmacolo­
gical receptor theory. Two types of receptors can be postulated as 
occurring at certain central postsynaptic endings. One receptor could 
be designated as Type E and could occur at the "excitatory" postsynap­
tic endings. Activation of Type E receptors would then give rise to 
excitatory postsynaptic potentials (EPSP) and general excitation, such 
as convulsions, would occur if enough of these receptors were activat­
ed. Conversely, another receptor designated as Type I could be present 
in the postsynaptic region of the "inhibitory" synapses and activation 
of these receptors would tend to reduce the activity of the excitatory 
synapses, and an inhibitory postsynaptic potential (IPSP) would be ob­
served. The overall synaptic activity of the central nervous system 
would then be the algebraic sum of the activities of the excitatory
and inhibitory synapses. The concept of excitatory and inhibitory 
synapses in the central nervous system has been postulated and in cer­
tain areas their presence has been demonstrated electrophysiologically 
by Ecoles, (18) and Grundfest (32). Furthermore, Purpura and Grundfest 
(7 1) have demonstrated that certain compounds such as pentylenetetrazol 
stimulate excitatory synapses, hence intensifying EPSP's recorded in 
cerebral and cerebellar cortical regions. The nature of the normal 
postsynaptic neurohumoral transmitters for the excitatory and inhibit­
ing synapses has not as yet been elucidated.
As has been observed by Purpura et al. (70) omega-omino acids do
not seem to activate the axodendritic endings but instead seem to block
EPSP's recorded from the excitatory postsynaptic areas and the IPSP's
recorded from the inhibitory postsynaptic areas. One must, therefore,
think of these agents in terms of their ability to induce a block of
Type E and Type I receptors in the respective postsynaptic regions. On
the basis of the data obtained in the present study and that obtained
by Purpura et al. (70), it would seem appropriate to suggest that omega-
amino acids with normal carbon chains of from CL-CL block predominating
2 ?
Type E receptors as evidenced by depression or reduction of the EPSP's. 
The optimal configuration for blockade of these receptors would seem to 
be: l) a 3-4 normal carbon chain? 2) a carboxyl group in the 1 posi­
tion; 3) and a terminal amino group in the 3 position for B-alanine or 
the 4 position for GAM. It may be seen from Table VI that the potency 
comparison of different omega-amino acids obtained in the present study 
agree closely with those obtained by Purpura et al. (70).
If the carbon chain length is reduced or lengthened (glycine or 5- 
amino-n-valeric acid) the affinity for the Type E receptor would be
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reduced. As the carbon chain length is increased above five carbons as 
represented by 6-amino-n-caproic acid and 8-amino-n-caprylic, affinity 
for the Type I receptors is increased and affinity for the Type E recep­
tors is reduced. The overalx effect observed might therefore manifest 
itself as excitation in terms of convulsive activity and blockade of re­
corded IPSP's. The results obtained in the present study indicate how­
ever, that this blockade of the Type E receptor at least is not entirely 
specific. With all of the compounds exhibiting loss of righting reflex, 
a period of clonus preceded the period of depression. The intensity of 
this clonus observed with the depressant omega-amino acids seemed to be 
least with glycine and greatest with 5-amino-n-valeric acid. This could 
be interpreted as indicating that the depressant omega-amino acids pos­
sess some affinity for Type I receptors as well as for Type E, and that 
the affinity for Type I receptors increases as the chain length increas­
es. This is substantiated in part by Purpura et al. (70) who obtained 
some indication of a dual site of action of C^-C^.omega-amino acids.
This dual action was manifest as a transient augmentation of cerebral 
dendritic negativity after the amino acids had been washed away from 
the cortical areas. In another report, Purpura et al. (67) observed that 
although GABA itself blocked excitatory synapses, its application to the 
cortex already treated with Cg or CQ omega-amino acids augmented their 
ability to block IPSP's. Again this might be interpreted as evidence for 
a dual site of action for GABA.
Other factors besides steric configuration may be necessary for 
optimal receptor blockade. The variable depressant activity observed 
with taurine, as compared with the consistent depressant effect induced 
by B-alanine, suggests that the carboxyl group is essential for activity
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In addition, tiie amino group must be on the terminal carbon since a few 
preliminary experiments showed that alpha-amino-butyric acid was hot ac­
tive in doses of 640 jag/20 g and the responses induced by B-amino-butyric 
acid in doses of 320-640 fig/20 g, though of the GABA-type, were not con­
sistent and reproducible. It would seem of interest also to study the 
secondary and tertiary amines of GABA. in order to assess the effects of 
increasing the size of the terminal group and altering the electrical 
charge on the nitrogen. If one postulates that attachment to the recep­
tor sites occurs at the two ends of the compound (i.e., carboxyl and ami­
no group) the alteration of the electrical configuration of the molecule 
by altering the electrical charge of either group should in turn reduce 
the affinity of the molecule for the receptor and hence its activity.
In one respect, the observation in the present study, that GABA did 
not antagonize strychnine induced convulsions is surprising in view of the 
suggestion of Eccles (18) that strychnine blocks inhibitory synapses in 
the central nervous system. If the convulsant activity of strychnine is 
due to a blockade of inhibitory synapses, then it would be suggestive 
that these convulsions are due to hyperactivity of excitatory synapses.
If GABA blocks excitatory synapses (70), then one might expect an antag­
onism of the strychnine-induced effects by this omega-amino acid. Jasper 
et al. (44) could not demonstrate antagonism between GABA and strychnine 
•in cats, utilizing the dendritic response elicited by local cortical stim­
ulation. Purpura et al. (66) noted that strychnine merely eliminated the 
surface positivity by blocking the inhibitory synapses that remain after 
GABA has blocked the excitatory synapses. This can hardly be interpreted 
as true antagonism. In the present study, at least two explanations for 
the observation that GABA does not alter strychnine-induced convulsions
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can be given. Purpura et al* (70) reported that GABA blocks only axo­
dendritic endings in the cerebral and cerebellar cortex and does not 
block excitatory axo-somatic synapses in the deeper areas of the central 
nervous system# Since, in the case of strychnine convulsions, one mighij 
expect the involvement of all central nervous system synapses (i. e., 
excitatory axo-somatic as well as axo-dendritic synapses would become 
hyperactive) it is not surprising that G A M  does not significantly alter 
the convulsions induced by strychnine. In addition, if strychnine tonic 
extensor convulsions are initiated predominantly from spinal cord re­
gions, it is conceivable that GABA, injected into the ventricles, does 
not diffuse in sufficient concentration into the lower central nervous 
system areas to prevent convulsions from these areas.
However, G A M  might be expected to antagonize pentylenetetrazol 
convulsions since Purpura and Grundfest (71) suggest that pentylene­
tetrazol induces convulsions by stimulating excitatory synapses in the 
brain. Furthermore, as stated previously, it has been demonstrated that 
QA3A blocks excitatory axo-dendritic synapses. If the contribution of 
these excitatory axo-dendritic synapses to the convulsive seizure in­
duced by pentylenetetraxol is great, then one would expect antagonism 
of pentylenetetrazol induced convulsions as noted with smaller doses 
of G A M  in the present study. Why potentiation of the pentylenetetra­
zol induced clonus occurs with higher doses of GABA is not obvious on 
the basis of present knowledge concerning the neurophysiological actions 
of GAM.
Why G A M  potentiates the convulsant activity of ammonium acetate 
and caffeine is not apparent. However, Chen et al. (l6) noted that 
reserpine tended to potentiate convulsions induced by maximal electro­
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shock, pentylenetetrazol and caffeine but did not potentiate convulsions 
induced by strychnine. It would seem, therefore, that reserpine and 
GABA could be used to advantage in the further elucidation of the mech­
anisms by which convulsions are induced by certain procedures.
SUMMARY
The effects of intracerebrally administered gamma-amino-butyric 
acid (GABA.) and related omega-amino acids and the anticonvulsant 
activity of GABA administered both systemically and intracerebrally 
were investigated in mice.
No evidence of neurotoxicity was observed with systemically ad­
ministered GABA in doses of 1 g/kg. Further, in doses of 1 g/kg 
or less, GABA did not protect the animals against the clonus due 
to pentylenetetrazol (0.5$ IV and 87.5 mg/kg SC) or minimal electro­
shock or tonic extensor seizures due to pentylenetetrazol (0.5$
IV) strychnine nitrate (1.25 mg/kg SC), caffeine (l°/o IV), ammonium 
acetate (5$ IV) or supramaximal electroshock. However it was 
possible to quantitate the anticonvulsant activity of three refer­
ence compounds against the appropriate convulsant test procedures. 
The technique of intracerebral administration of compounds to mice 
has been modified slightly and the responses obtained after the 
intracerebral administration of several compounds have been quan­
titated. Mice receiving GABA, glycine, B-alanine, and 5-amino-n- 
valeric acid showed biphasic responses, i.e. clonic movements 
followed by depression; the intensity of the depression was re­
lated to the dose of the compound administered. Intensity of the 
depression was quantitated in terms of loss of the righting reflex. 
GABA and B-alanine were of equimolar potency and were more active 
than glycine and 5-amino-n-valeric acid which were also equipotent. 
Alpha-amino-n-butyric acid was inactive in doses of 640 >ig/20 g or 
less. B-amino-n-butyric acid and taurine elicited GABA-type
±9
responses but these were not reproducible.
6-amino-n-caproic acid and 8-amino-n-caprylic acid produced 
clonus followed by tonic extensor seizures and death. The number 
of animals exhibiting tonic extensor seizures increased as the dose 
was increased. 8-amino-n-caprylic was approximately ten times as 
potent as 6-amino-caproic acid.
4. Intracerebrally administered GABA (20-60 /ig/20 g) protected against 
clonus due to pentylenetetrazol (0.5i° IV and 87.5 mg/kg SC) and 
minimal electroshock; but higher doses (80-160 jug/20 g) potentiated 
the clonus induced by the three procedures. Tonic extensor seiz­
ures induced by strychnine nitrate (1.25 mg/kg SC) or supramaximal 
electroshock were not affected by intracerebrally administered 
GABA. Protection from tonic extensor seizures and death due to 
pentylenetetrazol (0.5i° IV) was observed. A potentiation of the 
clonus and tonic extensor activity induced by caffeine (lfo IV) and 
tonic extensor activity due to ammonium acetate (5fo IV) was observ­
ed with intracerebrally administered GABA.
5. Possible reasons for the lack of neurotoxicity and anticonvulsant 
activity of systemically administered GABA have been given. The 
biphasic effects of intracerebrally administered GABA have been 
discussed. A structure-activity-relationship between the different 
omega-amino acids has been proposed, and on the basis of the present 
study and literature reports, two types of receptors designated as 
type E and type I have been speculated to exist at certain central 
nervous system synapses.
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